Robust Health-Care M&A Volume Ends 2020, Will Continue in 2021

Bloomberg Health Law & Business News

Gary W. Herschman and Anjana D. Patel, Members of the Firm in the Health Care & Life Sciences practice, in the firm’s Newark office, co-authored an article in Bloomberg Health Law & Business News, titled “Robust Health-Care M&A Volume Ends 2020, Will Continue in 2021.” The piece was also co-authored by Hector M. Torres, Managing Director at FocalPoint LLC, and Larry Kocot, Principal at KPMG LLP, and Carole Streicher, Partner at KPMG LLP. Zachary Taylor, Associate in the Health Care & Life Sciences practice, also contributed to the article.

Following is an excerpt:

The volume of announced and closed health-care industry deals in December (222) was the highest of any month in 2020 and 2021 should remain a strong year for deals as the Biden administration doubles down on the pandemic and economic recovery, vaccine distribution accelerates, new therapeutics come to market, and providers and health technology companies innovate to meet evolving patient needs.

In 2020, total deal volume for the year ended at 1,936. Although deal volume slowed in Q2 (354 announced/closed) as the country faced the beginning of the Covid-19 pandemic, investor activity accelerated through the second half of the year: Q3 (496) and Q4 (610).

While the economy as a whole was deeply impacted by the effects of the pandemic, the health-care and life sciences industry appears to have remained largely resilient through the significant disruptions caused by Covid-19.